Dynasty Wealth Management LLC Makes New $234,000 Investment in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Dynasty Wealth Management LLC bought a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 558 shares of the company’s stock, valued at approximately $234,000.

Other institutional investors also recently bought and sold shares of the company. Golden State Wealth Management LLC lifted its holdings in IDEXX Laboratories by 3,766.7% in the 1st quarter. Golden State Wealth Management LLC now owns 116 shares of the company’s stock valued at $49,000 after purchasing an additional 113 shares in the last quarter. Sagespring Wealth Partners LLC acquired a new stake in IDEXX Laboratories in the first quarter valued at approximately $229,000. Banque Transatlantique SA acquired a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $2,681,000. Wealth Enhancement Advisory Services LLC boosted its stake in shares of IDEXX Laboratories by 13.0% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 25,553 shares of the company’s stock valued at $10,731,000 after buying an additional 2,931 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of IDEXX Laboratories by 42.7% during the 1st quarter. GAMMA Investing LLC now owns 2,187 shares of the company’s stock valued at $918,000 after buying an additional 654 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on IDXX shares. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, July 12th. Jefferies Financial Group started coverage on IDEXX Laboratories in a research note on Tuesday, July 1st. They issued a “buy” rating and a $625.00 price target on the stock. Morgan Stanley lifted their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the company an “overweight” rating in a research note on Monday, May 5th. Stifel Nicolaus boosted their price target on IDEXX Laboratories from $510.00 to $540.00 and gave the company a “hold” rating in a research note on Wednesday, July 2nd. Finally, Leerink Partners boosted their target price on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $560.33.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director M Anne Szostak sold 1,260 shares of the firm’s stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the sale, the director owned 1,801 shares in the company, valued at approximately $922,724.34. This trade represents a 41.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.98% of the stock is currently owned by company insiders.

IDEXX Laboratories Stock Down 0.4%

Shares of NASDAQ IDXX opened at $518.71 on Friday. The stock has a market capitalization of $41.71 billion, a PE ratio of 47.94, a price-to-earnings-growth ratio of 3.80 and a beta of 1.54. The company has a current ratio of 1.16, a quick ratio of 0.81 and a debt-to-equity ratio of 0.31. The stock’s fifty day simple moving average is $523.12 and its two-hundred day simple moving average is $462.00. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $549.52.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The business had revenue of $998.43 million for the quarter, compared to analysts’ expectations of $998.25 million. During the same period in the previous year, the firm posted $2.71 EPS. The business’s revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.